







PATIENTS HAVE AN ALTERNATIVE TO EXPENSIVE BIOLOGIC MEDICINES

Biologics are innovative treatment options for a wide range of patients with:

-  Rheumatoid arthritis
-  Cancer
-  Crohn's disease
-  Other chronic or life-threatening diseases

WHAT ARE BIOLOGICS?

Biologic medicines (or reference products) are large-molecule products that involve complex research, development and manufacturing processes. They are often expensive, limiting access for many patients.

WHAT ARE BIOSIMILARS?

Biosimilars are FDA-approved alternatives to reference biologics – **much like generic drugs** – that provide treatment options for patients who need biologic medicines to manage their conditions.

ROUGHLY **2%**

Of U.S. patients use biologics

Source: www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023

OVER **50%**

Of prescription drug spending in the U.S. is for biologics

Source: www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023

Biosimilars have the potential to save the health care system \$54 billion over the next ten years and offer access for needed treatments to over 1.2 million patients.

Source: www.rand.org/pubs/periodicals/health-quarterly/issues/v7/n4/03.html
Source: www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023

WHAT YOU NEED TO KNOW ABOUT BIOSIMILARS

Stay informed about biosimilars so you can spot misinformation.

- FACT**
FDA-approved biosimilars have highly similar quality, safety and efficacy to existing biologic medicines.
- FACT**
There is no clinically meaningful difference between a biosimilar and its reference product.
- FACT**
It's safe to switch from a biologic to a biosimilar.

To learn more, visit the [FDA](https://www.fda.gov)

THE NAME GAME

The FDA provides [this valuable resource](#) to help prevent naming confusion between a biosimilar and its biologic counterpart to make sure patients receive the correct treatment option.

Demand Change



- Tear down the barriers preventing patient access to biosimilars.
- Reduce patient out-of-pocket costs for biosimilars.
- Increase reimbursement for lower-cost biosimilars to incentivize education and prescribing.
- Create a biosimilar tier in Medicare Part D with lower cost-sharing for patients.

Biosimilars benefit us all

Wider access to biosimilars benefits patients, doctors and payers. Let's increase access to biosimilars.

Learn more about biosimilars
biosimilarscouncil.org/advocacy

